Thursday 16 October, 2025
Introduction Modelling of longitudinal tumor size metrics has gained traction in Oncology to complement traditional endpoints. Several models have been…
Read morePoster: Drug/Disease Modelling - Oncology
Application of Quantitative Systems Pharmacology (QSP) Approach to Guide Development of a Bispecific CD40-EpCAM Antibody, KK2269.
Thursday 16 October, 2025
Introduction: KK2269 is a novel bispecific antibody that binds to CD40 on antigen presenting cells and epithelial cell adhesion molecule…
Read moreA semi-mechanistic approach to model simultaneously the ADC, total mAb and cytotoxic payload of sacituzumab tirumotecan
Thursday 16 October, 2025
Introduction: Antibody-Drug Conjugates (ADCs) are a promising class of targeted cancer therapies that combine the specificity of monoclonal antibodies (mAbs)…
Read moreSemi-mechanistic model of antitumor response after oncolytic virus administration
Thursday 16 October, 2025
Introduction: Oncolytic viruses (OVs)1,2 show promise as an oncologic therapeutic due to their ability to replicate in and kill tumor…
Read moreA Physiologically Based Pharmacokinetic Model for Pemetrexed in Metastatic EGFR-Mutated NSCLC: Application and prospective validation in the context of FLAURA2 Phase III
Thursday 16 October, 2025
Introduction: Pemetrexed is an essential antifolate agent frequently prescribed alongside platinum compounds to treat metastatic non-squamous NSCLC. Similarly to natural…
Read moreUse of physiologically-based pharmacokinetic modelling to assess the drug-disease interaction of caffeine in cancer subjects and the influence of cytokine-mediated CYP1A2 suppression
Thursday 16 October, 2025
Introduction: Caffeine, a psychostimulant consumed by 80% of world population every day, is predominantly metabolized by cytochrome P450 enzyme, CYP1A2…
Read morePopulation Pharmacokinetics of Intravenous Methotrexate: A Model-Based Meta-Analysis Integrating Individual Patient Data from Three Independent Studies
Thursday 16 October, 2025
Introduction: Numerous population pharmacokinetic (popPK) studies of MTX have been published, characterizing MTX disposition in the context of oncology among…
Read moreAssessment of S65487 PK differences from therapeutic doses to microdose: exploring linear and nonlinear processes
Thursday 16 October, 2025
Objectives S65487 is an intravenously administered BCL2 inhibitor which underwent clinical development in hematological malignancies. Before clinical trials at therapeutic…
Read moreAn enhanced PBPK model for predicting mRNA-encoded therapeutic trafficking in mice
Thursday 16 October, 2025
Introduction/Objectives: The interest in mRNA-encoded therapeutics has surged in recent years, particularly in the context of tumor therapies. Despite promising…
Read moreIntegrating Clinical Utility Index in Early Phase Oncology Trials: A Case Study with Antibody-Drug Conjugates
Thursday 16 October, 2025
Introduction/Objectives: Clinical Utility Indexes (CUIs) offer a quantitative and combined measure of efficacy and safety within a highly expandable platform….
Read more